These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. Ryan MC; Itsiopoulos C; Thodis T; Ward G; Trost N; Hofferberth S; O'Dea K; Desmond PV; Johnson NA; Wilson AM J Hepatol; 2013 Jul; 59(1):138-43. PubMed ID: 23485520 [TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator inhibitor-1, monocyte chemoattractant protein-1, e-selectin and C-reactive protein levels in response to 4-week very-high-fructose or -glucose diets. Silbernagel G; Machann J; Häring HU; Fritsche A; Peter A Eur J Clin Nutr; 2014 Jan; 68(1):97-100. PubMed ID: 24219891 [TBL] [Abstract][Full Text] [Related]
24. Fructose supplementation worsens the deleterious effects of short-term high-fat feeding on hepatic steatosis and lipid metabolism in adult rats. Crescenzo R; Bianco F; Coppola P; Mazzoli A; Tussellino M; Carotenuto R; Liverini G; Iossa S Exp Physiol; 2014 Sep; 99(9):1203-13. PubMed ID: 24972835 [TBL] [Abstract][Full Text] [Related]
25. Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease. Jin R; Krasinskas A; Le NA; Konomi JV; Holzberg J; Romero R; Vos MB Pediatr Obes; 2018 Jan; 13(1):23-29. PubMed ID: 27764892 [TBL] [Abstract][Full Text] [Related]
26. Oral citrulline supplementation protects female mice from the development of non-alcoholic fatty liver disease (NAFLD). Sellmann C; Jin CJ; Engstler AJ; De Bandt JP; Bergheim I Eur J Nutr; 2017 Dec; 56(8):2519-2527. PubMed ID: 27496089 [TBL] [Abstract][Full Text] [Related]
27. Gut Permeability Might be Improved by Dietary Fiber in Individuals with Nonalcoholic Fatty Liver Disease (NAFLD) Undergoing Weight Reduction. Krawczyk M; Maciejewska D; Ryterska K; Czerwińka-Rogowska M; Jamioł-Milc D; Skonieczna-Żydecka K; Milkiewicz P; Raszeja-Wyszomirska J; Stachowska E Nutrients; 2018 Nov; 10(11):. PubMed ID: 30453660 [TBL] [Abstract][Full Text] [Related]
28. A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts. Koh YC; Lin YC; Lee PS; Lu TJ; Lin KY; Pan MH Food Funct; 2020 Sep; 11(9):7545-7560. PubMed ID: 32815965 [TBL] [Abstract][Full Text] [Related]
29. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. Zelber-Sagi S; Ratziu V; Oren R World J Gastroenterol; 2011 Aug; 17(29):3377-89. PubMed ID: 21876630 [TBL] [Abstract][Full Text] [Related]
30. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease. Softic S; Cohen DE; Kahn CR Dig Dis Sci; 2016 May; 61(5):1282-93. PubMed ID: 26856717 [TBL] [Abstract][Full Text] [Related]
31. Short-Term Intake of a Fructose-, Fat- and Cholesterol-Rich Diet Causes Hepatic Steatosis in Mice: Effect of Antibiotic Treatment. Brandt A; Jin CJ; Nolte K; Sellmann C; Engstler AJ; Bergheim I Nutrients; 2017 Sep; 9(9):. PubMed ID: 28906444 [TBL] [Abstract][Full Text] [Related]
32. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Browning JD; Baker JA; Rogers T; Davis J; Satapati S; Burgess SC Am J Clin Nutr; 2011 May; 93(5):1048-52. PubMed ID: 21367948 [TBL] [Abstract][Full Text] [Related]
33. Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjects. Smajis S; Gajdošík M; Pfleger L; Traussnigg S; Kienbacher C; Halilbasic E; Ranzenberger-Haider T; Stangl A; Beiglböck H; Wolf P; Lamp T; Hofer A; Gastaldelli A; Barbieri C; Luger A; Trattnig S; Kautzky-Willer A; Krššák M; Trauner M; Krebs M Am J Clin Nutr; 2020 Feb; 111(2):369-377. PubMed ID: 31796953 [TBL] [Abstract][Full Text] [Related]
34. Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD). Alwahsh SM; Gebhardt R Arch Toxicol; 2017 Apr; 91(4):1545-1563. PubMed ID: 27995280 [TBL] [Abstract][Full Text] [Related]
35. Role of diet and nutritional management in non-alcoholic fatty liver disease. Fan JG; Cao HX J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():81-7. PubMed ID: 24251710 [TBL] [Abstract][Full Text] [Related]
36. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Kantartzis K; Thamer C; Peter A; Machann J; Schick F; Schraml C; Königsrainer A; Königsrainer I; Kröber S; Niess A; Fritsche A; Häring HU; Stefan N Gut; 2009 Sep; 58(9):1281-8. PubMed ID: 19074179 [TBL] [Abstract][Full Text] [Related]
37. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial. Friedrich D; Marschall HU; Lammert F BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129 [TBL] [Abstract][Full Text] [Related]
38. Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial. Cai H; Qin YL; Shi ZY; Chen JH; Zeng MJ; Zhou W; Chen RQ; Chen ZY BMC Gastroenterol; 2019 Dec; 19(1):219. PubMed ID: 31852444 [TBL] [Abstract][Full Text] [Related]